1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Profiling Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Profiling Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario for Cancer Profiling
5.2. Cancer Epidemiology, by Region
5.3. Technological Advancements in Cancer Profiling Technology
5.4. COVID-19 Impact on the Industry
6. Global Cancer Profiling Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Instruments
6.3.1.1. Immunohistochemistry Analyzers
6.3.1.2. In Situ Hybridization Instruments
6.3.1.3. Polymerase Chain Reaction Instruments
6.3.1.4. DNA Sequencers
6.3.1.5. Fragment Analyzers
6.3.2. Consumables
6.3.2.1. Reagents & Kits
6.3.2.2. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Cancer Profiling Market Analysis and Forecast, by Technology
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017-2031
7.3.1. Immunohistochemistry
7.3.2. Next Generation Sequencing
7.3.3. Polymerase Chain Reaction
7.3.4. In Situ Hybridization
7.3.5. Microarrays
7.3.6. Fragment Analysis
7.3.7. Others
7.4. Market Attractiveness Analysis, by Technology
8. Global Cancer Profiling Market Analysis and Forecast, by Cancer Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Cancer Type, 2017-2031
8.3.1. Breast Cancer
8.3.2. Lung Cancer
8.3.3. Colorectal Cancer
8.3.4. Prostate Cancer
8.3.5. Prostate Cancer
8.3.6. Melanoma
8.3.7. Others
8.4. Market Attractiveness Analysis, by Cancer Type
9. Global Cancer Profiling Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Cancer Research Institutes
9.3.4. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Cancer Profiling Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Cancer Profiling Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Instruments
11.2.1.1. Immunohistochemistry Analyzers
11.2.1.2. In Situ Hybridization Instruments
11.2.1.3. Polymerase Chain Reaction Instruments
11.2.1.4. DNA Sequencers
11.2.1.5. Fragment Analyzers
11.2.2. Consumables
11.2.2.1. Reagents & Kits
11.2.2.2. Others
11.3. Market Value Forecast, by Technology, 2017-2031
11.3.1. Immunohistochemistry
11.3.2. Next Generation Sequencing
11.3.3. Polymerase Chain Reaction
11.3.4. In Situ Hybridization
11.3.5. Microarrays
11.3.6. Fragment Analysis
11.3.7. Others
11.4. Market Value Forecast, by Cancer Type, 2017-2031
11.4.1. Breast Cancer
11.4.2. Lung Cancer
11.4.3. Colorectal Cancer
11.4.4. Prostate Cancer
11.4.5. Prostate Cancer
11.4.6. Melanoma
11.4.7. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Cancer Research Institutes
11.5.4. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Technology
11.7.3. By Cancer Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Cancer Profiling Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Instruments
12.2.1.1. Immunohistochemistry Analyzers
12.2.1.2. In Situ Hybridization Instruments
12.2.1.3. Polymerase Chain Reaction Instruments
12.2.1.4. DNA Sequencers
12.2.1.5. Fragment Analyzers
12.2.2. Consumables
12.2.2.1. Reagents & Kits
12.2.2.2. Others
12.3. Market Value Forecast, by Technology, 2017-2031
12.3.1. Immunohistochemistry
12.3.2. Next Generation Sequencing
12.3.3. Polymerase Chain Reaction
12.3.4. In Situ Hybridization
12.3.5. Microarrays
12.3.6. Fragment Analysis
12.3.7. Others
12.4. Market Value Forecast, by Cancer Type, 2017-2031
12.4.1. Breast Cancer
12.4.2. Lung Cancer
12.4.3. Colorectal Cancer
12.4.4. Prostate Cancer
12.4.5. Prostate Cancer
12.4.6. Melanoma
12.4.7. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Cancer Research Institutes
12.5.4. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Technology
12.7.3. By Cancer Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Cancer Profiling Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Instruments
13.2.1.1. Immunohistochemistry Analyzers
13.2.1.2. In Situ Hybridization Instruments
13.2.1.3. Polymerase Chain Reaction Instruments
13.2.1.4. DNA Sequencers
13.2.1.5. Fragment Analyzers
13.2.2. Consumables
13.2.2.1. Reagents & Kits
13.2.2.2. Others
13.3. Market Value Forecast, by Technology, 2017-2031
13.3.1. Immunohistochemistry
13.3.2. Next Generation Sequencing
13.3.3. Polymerase Chain Reaction
13.3.4. In Situ Hybridization
13.3.5. Microarrays
13.3.6. Fragment Analysis
13.3.7. Others
13.4. Market Value Forecast, by Cancer Type, 2017-2031
13.4.1. Breast Cancer
13.4.2. Lung Cancer
13.4.3. Colorectal Cancer
13.4.4. Prostate Cancer
13.4.5. Prostate Cancer
13.4.6. Melanoma
13.4.7. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Cancer Research Institutes
13.5.4. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Technology
13.7.3. By Cancer Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Cancer Profiling Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Instruments
14.2.1.1. Immunohistochemistry Analyzers
14.2.1.2. In Situ Hybridization Instruments
14.2.1.3. Polymerase Chain Reaction Instruments
14.2.1.4. DNA Sequencers
14.2.1.5. Fragment Analyzers
14.2.2. Consumables
14.2.2.1. Reagents & Kits
14.2.2.2. Others
14.3. Market Value Forecast, by Technology, 2017-2031
14.3.1. Immunohistochemistry
14.3.2. Next Generation Sequencing
14.3.3. Polymerase Chain Reaction
14.3.4. In Situ Hybridization
14.3.5. Microarrays
14.3.6. Fragment Analysis
14.3.7. Others
14.4. Market Value Forecast, by Cancer Type, 2017-2031
14.4.1. Breast Cancer
14.4.2. Lung Cancer
14.4.3. Colorectal Cancer
14.4.4. Prostate Cancer
14.4.5. Prostate Cancer
14.4.6. Melanoma
14.4.7. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Cancer Research Institutes
14.5.4. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Technology
14.7.3. By Cancer Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Cancer Profiling Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Instruments
15.2.1.1. Immunohistochemistry Analyzers
15.2.1.2. In Situ Hybridization Instruments
15.2.1.3. Polymerase Chain Reaction Instruments
15.2.1.4. DNA Sequencers
15.2.1.5. Fragment Analyzers
15.2.2. Consumables
15.2.2.1. Reagents & Kits
15.2.2.2. Others
15.3. Market Value Forecast, by Technology, 2017-2031
15.3.1. Immunohistochemistry
15.3.2. Next Generation Sequencing
15.3.3. Polymerase Chain Reaction
15.3.4. In Situ Hybridization
15.3.5. Microarrays
15.3.6. Fragment Analysis
15.3.7. Others
15.4. Market Value Forecast, by Cancer Type, 2017-2031
15.4.1. Breast Cancer
15.4.2. Lung Cancer
15.4.3. Colorectal Cancer
15.4.4. Prostate Cancer
15.4.5. Prostate Cancer
15.4.6. Melanoma
15.4.7. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Centers
15.5.3. Cancer Research Institutes
15.5.4. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Technology
15.7.3. By Cancer Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Abbott Laboratories
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Agilent Technologies Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. HTG Molecular Diagnostics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Illumina, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. PerkinElmer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. QIAGEN N.V.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Siemens Healthineers
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sysmex Corporation
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Thermo Fisher Scientific Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Hologic, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Guardant Health
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
